Search results
Asthma Triggers In Homes Can Send Kids to the ER—This Organization Is Working to Change That
Health.com· 1 day agoFor parents of children with asthma, witnessing an attack of severe symptoms can be a terrifying...
Research finds few moderate or severe asthma patients prescribed recommended inhaler regimen
Medical Xpress· 21 hours agoIn the United States, ICS-formoterol inhalers include Symbicort (budesonide-formoterol) and Dulera...
Eosinophilic Asthma
Health via Yahoo News· 3 days agoEosinophils are a type of immune system cell...management techniques are necessary. Targeted therapies, such as biologics, are essential for managing...
GSK boasts win for depemokimab in asthma trials
Clinical Trials Arena via Yahoo Finance· 1 day agoThe pharma giant announced the drug met primary endpoints in both the SWIFT-1 (NCT04719832) and SWIFT-2 (NCT4718103) trials of a reduction in...
GSK says its experimental drug reduced asthma attacks with only two doses a year
Quartz· 21 hours agoPeople suffering from a severe form of asthma could soon see their symptoms improve with a new...
Kids with asthma more likely to need hospital care during heat waves
United Press International via Yahoo News· 1 day agoHot and humid weather is a common asthma trigger, the American Lung Association says. Such weather...
GSK finds success in severe asthma drug trials
Becker’s Hospital Review· 1 day agoThe drug candidate, depemokimab, was measured in severe asthma patients with Type 2 inflammation characterized by blood eosinophil count, GSK said in a ...
GSK's Potential Blockbuster Asthma Drug Shows Promise in Latest Trial — 2nd Update
Morningstar· 1 day agoThe British pharmaceutical company's depemokimab drug reduced asthma attacks in late-stage trials for patients with severe eosinophilic ...
GSK Potential Blockbuster Asthma Drug Shows Promise in Latest Trial -- Update
Market Watch· 1 day agoBy Najat Kantouar and Helena Smolak GSK's experimental drug for asthma met its goals in the latest trial, moving a treatment with potential blockbuster sales...
GSK's SWIFT trial anthology shows long-acting treatment reduces asthma attacks
FierceBiotech· 1 day agoCenter stage is depemokimab, a biologic GSK calls “ultra-long-acting” with a binding affinity and high potency for interleukin-5. IL-5 is a known key protein for asthma patients ...
